

From the Department of Food Hygiene, College of Veterinary Medicine and State Veterinary Medical Institute, Helsinki, Finland.

SERUM AND MILK CONCENTRATIONS OF SEVERAL SULPHONAMIDES AND THEIR N⁴-ACETYL METABOLITES FOLLOWING ORAL ADMINISTRATION TO COWS

By

*Stefan Soback**, *Ulla Lamminsivu* and *Pirta Tapio*

SOBACK, STEFAN, U. LAMMINSIVU and P. TAPIO: *Serum and milk concentrations of several sulphonamides and their N⁴-acetyl metabolites following oral administration to cows.* Acta vet. scand. 1983, 24, 374—383. — Serum and milk concentrations of sulphonamides following oral administration of three commercial sulphonamide products to dairy cows were studied. The fate of the N⁴-acetyl derivatives of the compounds was also monitored. Sulfadimidine was found to have the slowest oral absorption rate compared to sulfamethoxy-pyridazine, sulfaphenazole and sulfanilamide. Sulfaphenazole was least absorbed. Excretion of the different sulfonamides into the milk was by passive diffusion and was best for the least ionized sulfanilamide followed by sulfadimidine and sulfamethoxy-pyridazine. The most ionized sulfaphenazole was not found in milk. Sulfanilamides was found to be readily acetylated (and sulfaphenazole to a lesser degree). N⁴-acetyl-sulfanilamide seemed to be actively secreted from blood into milk in the cow.

sulphonamides; pharmacokinetics; acetylation.

Oral administration of sulphonamides to dairy cows is common in treatment of infectious diseases such as mastitis.

The fundamental studies of *Rasmussen* (1958) and *Sisodia & Stowe* (1964) were followed by a multitude of reports on the pharmacokinetics and metabolism of various sulphonamide compounds in cows. Nevertheless, an evaluation of a particular sulphonamide compound as a therapeutic agent or as a source of residues is difficult due to dose, dosage interval and combination differences.

* Present address, Kimron Veterinary Institute, P OB 12 Beit Dagan, Israel.

The present report deals with sulphonamides and their N⁴-acetyl metabolite levels in serum and milk of cows following multiple oral treatments of 3 commercial sulphonamide products at recommended dosages. The potential therapeutic value of each product, based on the achieved serum and milk levels, is discussed. The serum levels and the excretion into milk of the N⁴-acetyl metabolites are also evaluated.

MATERIALS AND METHODS

Four Ayshire cows, each weighing 500—550 kg, were used in a triple cross over trial. Cows were at the end of their lactation period and produced 10—15 kg of milk daily. The state of udder health was determined before the trials by means of bacteriological tests conducted on aseptically collected milk and by the CMT (California Mastitis Test). The udder of 1 of the cows had 2 quarters shedding *Staphylococcus aureus* and the cell counts in the milk from the infected quarters were elevated.

Three commercial sulphonamide preparations were used. The first was a combination of two sulphonamides, sulfadimidine (SDD) and sulfanilamide (SA), ("Eutanil" Orion Pharmaceutical Co., Helsinki, Finland), at a 1:2 ratio, presented in a 30 g dosage envelope. The second preparation consisted of sulfamethoxypyridazine (SMP) and sulfanilamide (SA), ("Sulfamax", Lääke Oy, Turku, Finland), at a 1:3 ratio, presented in a 40 g dosage envelope. The third product contained sulfaphenazole (SPZ), ("Eftolon", Pfizer Co., Bruxelles, Belgium), in a 4 g dosage envelope.

The drugs were administered suspended in 1 l of water by ruminal intubation followed by 2—3 l water flush. The dosage of "Eutanil" per cow was 2×30 g, i.e. 60 g, on the first day and 30 g on each of the following 2 days. "Sulfamax" was given at 40 g per cow daily during 3 consecutive days. "Eftolon" was given at 4×4 g, i.e. 16 g per cow on the first day and 3×4 g (12 g) on each of the following 2 days. Dose schedules were according to the manufacturers instructions. A "wash out" period of 12 days was allowed between the administration of each preparation.

Blood and quarter milk samples were collected at 0,1,6,12 h and the at 12 h intervals until 72 h from the initial dosage. Serum and milk samples were kept frozen at -20°C until analyzed.

Microbiological analyses of quarter milk samples were made

according to the modified "Thermocult" method described by Soback & Lamminsivu (1979). The sensitivity limit of the method was 1.0 $\mu\text{g/ml}$.

Chemical analysis of serum and quarter milk samples was made by high performance liquid chromatography (HPLC), using a model M-6000 A pump, (Waters Associates, Inc., Milford, Mass.), 10 μl Wisp injector (Waters Ass.), LC-55 detector (Perkin-Elmer Corp., Norwalk, Conn.) UV₄₄₀, 254 nm. The column was a $\mu\text{Bondapak}$, C₁₈, 3.9 mm \times 50 cm (Waters Ass.). The samples were eluted with an acetonitrile - water - acetic acid mixture at ratio of 18:82:0.5 (20:80:0.5 for milk) at pH 3.2 at a flow rate of 1.5 ml/min (1.0 ml/min for milk) for SDD, SMP, SA, N⁴-AcSMP and N⁴-AcSA and at a ratio of 20:80:0.5 at pH 3.2 at a flow rate of 2.5 ml/min for SPZ and N₄-AcSPZ. For the separation of N⁴-AcSDD a ratio 27:73:0.25 was used.

The standard curve was linear in the range of 2—40 $\mu\text{g/ml}$ (1—20 $\mu\text{g/ml}$ in milk) for SA and N⁴-AcSA, 2 (4 for SMP) — 100 $\mu\text{g/ml}$ for SDD, SMP, N⁴-AcSDD and N⁴-AcSPZ. Recoveries of the internal standards were $95 \pm 3\%$ within the given ranges.

Serum samples were prepared for assay by mixing 4 ml (2 ml for SPZ) of acetonitrile with 1 ml of serum in a vortex to denature the proteins. This was followed by centrifugation for 10 min (15 min for SPZ) at 1000 \times g and the supernatant was used for the HPLC analysis.

Milk sample were prepared by adjusting the 2 ml (4 ml for SPZ) sample to pH 5.2—5.5 (5.6—5.8 for SPZ) with 1 mol/l acetic acid followed by extraction with 5.0 ml (4.0 ml for SPZ) ethylacetate for 10 min. The extract was centrifugated for 5 min at 1000 \times g. Two mls of the extract was evaporated in a N₂ flow at 40°C. The dry extract was dissolved in 2 ml of eluent and centrifugated. The supernatant was used for the HPLC analysis.

RESULTS

Serum concentrations of the parent compounds and their respective N⁴-acetyl derivatives measured by HPLC are given in Fig. 1 ("Eutanil"), Fig. 2 ("Sulfamax") and Fig. 3 ("Eftolon"). The values for N⁴-AcSDD and N⁴-AcSMP are not plotted since they were less than 2 $\mu\text{g/ml}$ and 4 $\mu\text{g/ml}$ respectively, thus below the levels of accurate measurement. Fig. 4 shows the respective concentrations of the compounds in the milk as determined by




Figure 1. The concentrations of sulfadimidine (SDD), sulfanilamide (SA) and N⁴-acetylsulfanilamide (N⁴-AcSA) in serum.




Figure 2. The concentrations of sulfamethoxyypyridazine (SMP), sulfanilamide (SA) and N⁴-acetylsulfanilamide (N⁴-AcSA) in serum.




Figure 3. The concentrations of sulfaphenazole (SPZ) and N⁴-acetylsulfaphenazole (N⁴-AcSPZ) in serum.




Figure 4. The concentrations of sulfadimidine (SDD), sulfamethoxyypyridazine (SMP), sulfanilamide (SA) and N⁴-acetylsulfanilamide (N⁴-AcSA) and the inhibition potential (IP) in milk. The "Sulfamax" above and the "Eutamil" below.

Table 1. Ionisation and protein binding of sulphonamides and theoretical and observed ratios.

| pKa | % Un-ionized serum pH 7.4 | b) milk pH 6.6 | c) Milk ultrafiltr. | | % Protein binding | AUC(a) milk | | AUC a) N ⁴ -Ac deriv. | |
|--------------------------------------|---------------------------|----------------|-------------------------------|-------------|-------------------|-------------------------------------|-----------------------------------|-------------------------------------|------|
| | | | Serum ultrafiltr. theoretical | theoretical | | AUC serum | serum | AUC parent serum | milk |
| Sulfadimidine | 7.4 | 50 | 86 | 0.58 | 70 | 18 | n.c. | n.c. | |
| Sulfamethoxyypyridazine | 6.7 | 17 | 56 | 0.28 | 76 | 8 | n.c. | n.c. | |
| Sulfaphenazole | 6.6 | 14 | 50 | 0.27 | 82 | n.c. | 31 | n.c. | |
| Sulfanilamide | 10.4 | 100 | 100 | 1.00 | 20 | 92 ¹ , 87 ² | 73 ¹ , 82 ² | 127 ¹ , 139 ² | |
| N ⁴ -acetyl sulfanilamide | 10.3 | 100 | 100 | 1.00 | 17—42 | 159 ¹ , 161 ² | —* | —* | |

a) AUC = Area Under the Concentration time curve (t = 0 — 72 h)

n.c. = not calculated

*) See sulfanilamide

1) "Eutamil"

2) "Sulfamax"

b) = 100

1 + antilog (pK_a - pH)

1 + antilog (pH_m - pK_a)

1 + antilog (pH_s - pK_a)

100

HPLC. The concentrations of SPZ and N⁴-AcSPZ did not reach the detection level (0.5 µg/ml) in milk and thus were not plotted. The results of the microbiological assay of drug concentrations in milk are given in terms of IP (inhibition potential) and are expressed as inhibition zone diameters (mm). Concentrations in Figs. 1—4 are given as means ± s.e.m. (standard error of mean). The proportions of sulphonamides and their N⁴-acetyl derivatives in serum and milk are given in Table 1.

DISCUSSION

A comparison of *in vitro* test results obtained by agar plate method with the expected *in vivo* efficacy is particularly difficult when sulphonamides are concerned because of the presence of sulphonamide antagonists in agars (*Neipp et al.* 1961, *Gudding* 1974, *Then* 1977). Therefore, a safety factor of 5—10 (*Otten & Plempe* 1975) has been suggested for the interpretation of therapeutic sulphonamide concentrations.

For the clinical interpretation of the results of the present study the use of the safety factor is questionable since 2 of the preparations studied were combinations of 2 compounds of different antimicrobial activity. Secondly the use of safety factor should be reconsidered since biasing factors in the agar result in higher MIC (Minimal Inhibitory Concentration) values than achieved in an optimal test.

All the drugs were detected in the serum within 1 h after their oral administration (Fig. 1, 2, 3) indicating fast absorption from the gastro-intestinal tract. Sulfadimidine reaches peak serum concentration more slowly than the other compounds having its peak at 12 h after administration, whereas the other compounds peaked at 6 h after the initial dose. *Luthman & Jacobson* (1979) found sulfadimidine to be more rapidly absorbed (peaks at 4 h) than sulfanilamide or sulfaphenazole (peak at 6 and 8 h), respectively). The disagreement might be due to experimental conditions especially considering the dosage.

The initial double dose of "Eutanil" seems to give this preparation an advantage because, compared to "Sulfamax", higher serum drug levels were produced (Fig. 1 and 2) although the total amount of sulfonamide given to the cows was the same. The concentrations of sulphonamide in serum after treatment with "Eftolon" (Fig. 3) were far lower than those reached by the 2

other preparations. If the amount of SPZ (16 g + 12 g + 12 g) is compared to the respective amounts of SDD (20 g + 10 g + 10 g) and SMP (10 g + 10 g + 10 g) then the concentration of SPZ in serum is only 1/4—1/5 of the concentrations of SDD and SMP at the same given dose. This indicates considerably less absorption of SPZ than SDD or SMP from the gastro-intestinal tract of the cow.

The amounts of N⁴-AcSA in the serum as measured by means of AUC (Area under the concentration-time curve) (Table 1) were 73 %—82 % of the amount of parent drug. This is much higher than the values (15 % ± 7) reported by *Nielsen* (1973). The experimental conditions in *Nielsen's* study and the present study were different. It is suggested that the time (2 h) after i.v. injection, when the acetyl derivative was measured by *Nielsen*, was not sufficiently long for measuring acetylation of this compound. *White & Evans* (1968) measured the "acetylator" phenotypes after oral ingestion of a sulphonamide from blood samples taken eight hours after drug administration. In a similar study, *Whelpton et al.* (1981) collected the samples at 6 h after oral dosage. From the other N⁴-acetyl derivatives measured, we found 31 % N⁴-AcSPZ from its parent compound and only trace amounts of N⁴-AcSDD or N⁴-AcSMP in the serum.

The excretion of the compounds into milk varied greatly as could be expected on the basis of their different pK_a values (Table 1); passage into milk was better at the higher pK_a value (*Rasmussen* 1958). Concentrations of SA in the milk were 87—92 % of the drug concentrations in the serum (Table 1). The theoretical concentration ratio of milk: serum for SA in ultrafiltrates is 1.0 (*Rasmussen* 1958). Since we measured the total (bound and un-bound) sulphonamide concentration, protein binding may be the reason for the lower values in the milk. The same is apparently true for milk: serum ratio of SDD which was 0.18 instead of the theoretical ratio 0.58, and the respective ratio for SMP which was 0.09 instead of the theoretical ratio 0.28. We could find only traces of SPZ in milk as this drug was also least un-ionized in serum (Table 1).

The concentration curve for SDD (Fig. 4) seems to be dominant for the IP ("Inhibition Potential") curve. The same is true in the case of SMP. This indicates that the antimicrobial effect of SA, though readily excreted to milk, is weak.

According to the results presented in Table 1, N⁴-acetyl sul-

fanilamide is present in milk at 1.6 times the concentration of the compound in serum. This is in agreement with the results of *Rasmussen* (1969) in goats and complement the results of *Nielsen* (1973) in cows suggesting active transport of N⁴AcSA from blood into milk.

The use of the products studied in this paper in veterinary antimicrobial therapy is, therefore, justified. Among the products tested "Eutanil" seemed to reach the highest while "Eftolon" reached the lowest concentrations of sulphonamides in milk when used according to the manufacturer's recommendations. These findings are of importance for treatment of acute mastitis when good drug excretion into the milk is desirable (*Ziv* 1975).

The high concentrations of SA and especially its N⁴-acetyl derivative may form a considerable residue problem since the derivative is not likely to be detected by microbiological tests routinely conducted for the presence of antimicrobial drug residues.

REFERENCES

- Gudding, R.*: The suitability of some media and peptones for sulphonamide testing. *Acta vet. scand.* 1974, 15, 366—380.
- Luthman, J. & S. O. Jacobson*: Serum koncentrationer av sulfonamider efter oral och perenteral tillförsel. (Serum concentrations of sulphonamides after oral and parenteral administration). *Svensk Vet. Tidn.* 1979, 31, 783—787.
- Neipp, L., W. Sackmann & J. Tripod*: Some new trends in the field of experimental research of sulphonamides. *Antibiotica & Chemotherapy*, Fortschritte 1961, 9, 19—82.
- Nielsen, P.*: The metabolism of four sulphonamides in cows. *Biochem. J.* 1973, 136, 1039—1045.
- Otten, H. & M. Plempel*: Antibiotica und Chemotherapeutika in einzel-darstellungen. (Antibiotics and chemotherapeutics in detail presentation). In: *Antibiotika — Fibel* by A. M. Walter & L. Heilmeyer. George Thieme Verlag, Stuttgart 1975.
- Rasmussen, F.*: Mammary excretion of sulphonamides. *Acta pharmacol. et toxicol.* 1958, 15, 139—148.
- Rasmussen, F.*: Active mammary excretion of N⁴-acetylated sulphanilamide. *Acta vet. scand.* 1969, 10, 402—403.
- Sisodia, C. S. & C. M. Stowe*: The mechanism of drug secretion into bovine milk. *Ann. N. Y. Acad. Sci.* 1964, 111, 650—661.
- Soback, S. & U. Lamminsivu*: The effect of protein binding on the excretion of three sulphonamide preparations in the milk of dairy cows, examined by chemical and microbiological methods. *Nord. Vet.-Med.* 1979, 31, 309—315.

- Then, R.*: Thymidine content in commercially prepared media. *Zbl. Bakt. A.* 1977, 237, 372—377.
- Whelpton, R., G. Watkins & H. Curry*: Bratton-Marchall and Liquid-Chromatographic Methods compared for determination of sulfamethazine acetylator status. *Clin. Chem.* 1981, 27, 1911—1914.
- White, T. A. & D. A. P. Evans*: The acetylation of sulfamethazine and sulfamethoxy pyridazine by human subjects. *Clin. Pharmacol. Ther.* 1967, 9, 80—88.
- Ziv, G.*: Pharmacokinetic concepts for systemic and intramammary antibiotic treatment in lactating and dry cows. *Proc. International Dairy Federation, Seminar on Mastitis Control.* (Dodd, F. H. et al. eds.), Brussels, Belgium 1975, pp. 314—340.

SAMMANFATTNING

Serum- och mjölkkoncentrationer av flera sulfonamider samt deras N⁴-acetyl metaboliter efter oral giva åt kor.

Serum och mjölkkoncentrationer av sulfonamider efter oralt bruk av tre kommersiella sulfonamidprodukter på mjölkkor undersöktes. Likaledes kartlades händelseförloppet hos komponenternas N⁴-acetylderivater. Sulfadimidin befanns uppvisa det långsammaste orala absorptionsförloppet jämfört med sulfametyloxyridazin, sulfafenazol och sulfanilamid. Sulfafenazol absorberades minst.

Avsöndring av de olika sulfonamiderna i mjölken var genom passiv diffusion högst hos det lägst-ioniserade sulfanilamid, därefter sulfadimidin och sulfametyloxyridazin. Det högst ioniserade sulfafenazol förekom inte i mjölken. Endast sulfanilamid (sulfafenazol i mindre grad) visade sig vara lätt acetylerat. N⁴-acetylsulfanilamid tycks utsöndras aktivt från blodet till mjölken hos kon.

(Received October 12, 1983).

Reprints may be requested from: Stefan Soback, Kimron Veterinary Institute, POB 12, Beit Dagan, Israel.